Long‐term remission with rituximab therapy in a five‐year‐old patient with pemphigus vulgaris

JDDG: Journal der Deutschen Dermatologischen GesellschaftEarly View CLINICAL LETTER Long-term remission with rituximab therapy in a five-year-old patient with pemphigus vulgaris Bilgen Erdoğan, Bilgen Erdoğan Department of Dermatology, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, TurkeySearch for more papers by this authorElif Nur Meral, Corresponding Author Elif Nur Meral [email protected] orcid.org/0000-0002-7425-2265 Department of Dermatology, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey Correspondence Elif Nur Meral, MD, Department of Dermatology, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Bakırkoy, 34147, Istanbul, Turkey. Email: [email protected]Search for more papers by this authorZeynep Topkarci, Zeynep Topkarci Department of Dermatology, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, TurkeySearch for more papers by this authorNevin Hatipoğlu, Nevin Hatipoğlu Department of Pediatric Infectious Diseases, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, TurkeySearch for more papers by this authorAyşe Kavak, Ayşe Kavak Department of Dermatology, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, TurkeySearch for more papers by this author Bilgen Erdoğan, Bilgen Erdoğan Department of Dermatology, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, TurkeySearch for more papers by this authorElif Nur Meral, Corresponding Author Elif Nur Meral [email protected] orcid.org/0000-0002-7425-2265 Department of Dermatology, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey Correspondence Elif Nur Meral, MD, Department of Dermatology, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Bakırkoy, 34147, Istanbul, Turkey. Email: [email protected]Search for more papers by this authorZeynep Topkarci, Zeynep Topkarci Department of Dermatology, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, TurkeySearch for more papers by this authorNevin Hatipoğlu, Nevin Hatipoğlu Department of Pediatric Infectious Diseases, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, TurkeySearch for more papers by this authorAyşe Kavak, Ayşe Kavak Department of Dermatology, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, TurkeySearch for more papers by this author First published: 27 November 2023 https://doi.org/10.1111/ddg.15299Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Sillevis Smitt JH. Pemphigus vulgaris in childhood: clinical features, treatment, and prognosis. Pediatr Dermatol. 1985; 2(3): 185-190. 10.1111/j.1525-1470.1985.tb01049.x CASPubMedGoogle Scholar 2Gürcan H, Mabrouk D, Razzaque Ahmed A. Management of pemphigus in pediatric patients. Minerva Pediatr. 2011; 63(4): 279-291. PubMedWeb of Science®Google Scholar 3Cerny T, Borisch B, Introna M, et al. Mechanism of action of rituximab. Anticancer Drugs. 2002; 13(Suppl2): 3-10. 10.1097/00001813-200211002-00002 Google Scholar 4Hertl M, Zillikens D, Borradori L, et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges. 2008; 6(5): 366-373. 10.1111/j.1610-0387.2007.06602.x CASPubMedWeb of Science®Google Scholar 5Frampton JE. Rituximab: A review in pemphigus vulgaris. Am J Clin Dermatol. 2020; 21(1): 149-156. 10.1007/s40257-019-00497-9 PubMedWeb of Science®Google Scholar 6Holtsche MM, Boch K, Schmidt E. Autoimmune bullous dermatoses. J Dtsch Dermatol Ges. 2023; 21(4): 405-412. 10.1111/ddg.15046_g Google Scholar 7Patel MH, Brumfiel CM, Bohrer N, Marsch AF. Efficacy of rituximab in pediatric pemphigus: a literature review. JAAD Int. 2022; 6: 6-10. 10.1016/j.jdin.2021.10.002 PubMedGoogle Scholar 8Quartier P, Brethon B, Philippet P, et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet. 2001; 358(9292): 1511-1513. 10.1016/S0140-6736(01)06573-4 CASPubMedWeb of Science®Google Scholar 9Kincaid L, Weinstein M. Rituximab therapy for childhood pemphigus vulgaris. Pediatr Dermatol. 2016; 33(2): e61-e64. 10.1111/pde.12744 PubMedWeb of Science®Google Scholar 10Reguiai Z, Tabary T, Maizières M, Bernard P. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up. J Am Acad Dermatol. 2012; 67(4): 623-629. 10.1016/j.jaad.2011.12.019 CASPubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation